APEIRON Biologics Company

Apeiron Biologics is a biotech company that focuses on the discovery and development of novel cancer immunotherapies.
A drug candidate developed by APEIRON Biologics named APN01 is being tested in China in a phase one pilot trial as a treatment for COVID-19. APN01 is based on research conducted by a professor at the University of British Columbia for treating SARS. The research revealed that the ACE2 protein was the main receptor for the SARS virus.

Headquarters: Austria
Funding Status: N/A
Employee Number: N/A
Investment Stage: N/A
Number Of Exists: N/A
Technology: COVID
Investor Type: N/A
Founded Date: N/A
Industry: Vaccine/Drug